Cargando…
Anti-Angiogenesis Drug Discovery and Development
The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, etc. Efforts to understand the molecular basis, both for inh...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Singapore :
Bentham Science Publishers,
2020.
|
| Colección: | Anti-Angiogenesis Drug Discovery and Development Ser.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Mu 4500 | ||
|---|---|---|---|
| 001 | EBSCO_on1206397734 | ||
| 003 | OCoLC | ||
| 005 | 20231017213018.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 201114s2020 si o ||| 0 eng d | ||
| 040 | |a EBLCP |b eng |c EBLCP |d YDX |d EBLCP |d N$T |d OCLCF |d OCLCO |d K6U |d OCLCQ |d OCLCO | ||
| 019 | |a 1200197820 | ||
| 020 | |a 9811432872 | ||
| 020 | |a 9789811432873 |q (electronic bk.) | ||
| 035 | |a (OCoLC)1206397734 |z (OCoLC)1200197820 | ||
| 050 | 4 | |a RC271.N46 | |
| 082 | 0 | 4 | |a 600 |
| 049 | |a UAMI | ||
| 100 | 1 | |a Atta-ur-Rahman. | |
| 245 | 1 | 0 | |a Anti-Angiogenesis Drug Discovery and Development |h [electronic resource]. |
| 260 | |a Singapore : |b Bentham Science Publishers, |c 2020. | ||
| 300 | |a 1 online resource (212 p.). | ||
| 490 | 1 | |a Anti-Angiogenesis Drug Discovery and Development Ser. | |
| 500 | |a Description based upon print version of record. | ||
| 520 | |a The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, etc. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results.Anti-angiogenesis Drug Discovery and Development provides an excellent compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery scien. | ||
| 505 | 0 | |a Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- Therapeutic Targeting of the Tumor Vasculature: Past, Present and Future -- Peace Mabeta1,*, Mike Sathekge2 and Vanessa Steenkamp3 -- INTRODUCTION -- ANGIOGENESIS IN TUMOR PROGRESSION -- The Tumor Vasculature -- Importance of Vascular Endothelial Growth Factor Signaling in Cancer -- Therapeutic Targeting of Vascular Endothelial Growth Factor -- BEYOND BEVACIZUMAB -- Ramucirumab -- Apatinib -- Effectiveness of Anti-VEGF Versus Anti-VEGFR Therapy | |
| 505 | 8 | |a DEVELOPMENT OF RESISTANCE TO VEGF/VEGFR-2 TARGETING DRUGS -- Platelet-Derived Growth Factor Pathway -- Fibroblast Growth Factor Signaling in Anti-Cancer Therapy -- Angiopoietin-Tie Pathway in Therapeutic Anti-Angiogenesis -- THERAPEUTIC TARGETING OF MULTIPLE ANGIOGENIC PATHWAYS -- Multi-Targeting Tyrosine Kinase Inhibitors -- Sorafenib -- Sunitinib -- Axitinib -- Pazopanib -- Nintedanib -- Multi-Targeting Versus Mono-Targeting AIs -- FUSION PEPTIDES AND DECOY RECEPTORS -- Aflibercept -- Abexinostat and Panobinostat Attenuate Hypoxia -- IMMUNE CELLS AND THE EFFECTIVENESS OF ANGIOGENESIS INHIBITORS | |
| 505 | 8 | |a OVERCOMING INFLAMMATION -- ANGIOGENESIS INHIBITORS AND IMMUNOTHERAPY -- Normalization of the Tumor Vasculature -- FUTURE PERSPECTIVE -- IMAGING BIOMARKERS IN ANGIOGENESIS -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Anti-angiogenic Mechanism, Biochemical Factors' Roles, Therapeutic Agents, and Under Clinical Trial Drugs for Breast and Prostate Cancers -- Varsha M. Singh1, Shilpa J. Newati1, Mohammad Yusuf2, Alexandre Bridoux3,4, Salman A. A. Mohammed5, Naseem Akhtar6 and Riaz A. Khan1,5,* -- INTRODUCTION: THE ANGIOGENESIS AND CANCERS | |
| 505 | 8 | |a ANGIOGENIC BIOMECHANISMS: NORMAL VERSUS TUMOR-INDUCED -- Tumor Vasculature -- Operational Signaling Pathways in Tumor -- Angiogenic Promoters and their Involvement in Breast Cancer -- Angiogenin -- Vascular Endothelial Growth Factors (VEGFs) -- Interleukins -- Fibroblast Growth Factors (FGF) -- Matrix MetalloProteinases (MMPs) and Matrix Remodeling -- Angiopoietins -- Roles of Integrins in Tumorigenesis -- ANGIOGENIC INHIBITORS -- Interferons -- Endostatin -- Angiostatin -- Thrombospondin -- Decorin -- Commercially Aailable Angiogenic Inhibitors | |
| 505 | 8 | |a CLINICAL TRIALS TOWARDS ANTI-ANGIOGENIC DRUGS DEVELOPMENT -- Bevacizumab -- Cilengitide -- Aflibercept -- Ramucirumab -- Sorafenib -- Sunitinib -- Vandetanib -- Axitinib -- Pazopanib -- Drugs Approved to Treat Breast Cancers -- RELATIONSHIP BETWEEN INFLAMMATION, ANGIOGENESIS, AND COAGULATION IN PROSTATE CANCERS -- ANGIOGENESIS, THROMBOSIS AND INFLAMMATION MEDIATORS' CROSSTALK -- 6.1. Angiogenesis and Inflammation Mediators' Crosstalk -- Angiogenic Capability of Tumors and Thromboembolic Crosstalk -- CLINICAL TRIALS FOR ANTI-ANGIOGENIC PROSTATE CANCER DRUG DEVELOPMENT | |
| 590 | |a eBooks on EBSCOhost |b EBSCO eBook Subscription Academic Collection - Worldwide | ||
| 650 | 0 | |a Neovascularization inhibitors. | |
| 650 | 0 | |a Neovascularization. | |
| 650 | 0 | |a Drug development. | |
| 650 | 2 | |a Angiogenesis Inhibitors | |
| 650 | 2 | |a Neovascularization, Pathologic | |
| 650 | 6 | |a Néovascularisation |x Inhibiteurs. | |
| 650 | 6 | |a Néovascularisation. | |
| 650 | 6 | |a Médicaments |x Développement. | |
| 650 | 7 | |a Drug development |2 fast | |
| 650 | 7 | |a Neovascularization |2 fast | |
| 650 | 7 | |a Neovascularization inhibitors |2 fast | |
| 700 | 1 | |a Choudhary, M. Iqbal. | |
| 776 | 0 | 8 | |i Print version: |a Atta-ur-Rahman |t Anti-Angiogenesis Drug Discovery and Development: Volume 5 |d Singapore : Bentham Science Publishers,c2020 |z 9789811432866 |
| 830 | 0 | |a Anti-Angiogenesis Drug Discovery and Development Ser. | |
| 856 | 4 | 0 | |u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=2649042 |z Texto completo |
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL6388633 | ||
| 938 | |a YBP Library Services |b YANK |n 301624539 | ||
| 938 | |a EBSCOhost |b EBSC |n 2649042 | ||
| 994 | |a 92 |b IZTAP | ||